Dr. Matsangou presents research on GSK-3B and its role in head and neck carcinoma at the AACR meeting in Washington, DC. (poster)
March 1, 2017
Dr. Francis J. Giles joins Actuate as Chief Medical Officer.
March 29, 2016
FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma.
December 18, 2015
Actuate receives a favorable FDA Written Response to our Pre-IND Plan for the development of 9-ING-41. The FDA laid out a very clear path on tasks necessary to complete in order to submit an IND, which sets the company up well for advancing 9-ING-41 into the clinic, and ultimately, to effectively treating patients.
December 11, 2015
Actuate completes initial financing.
November 19, 2015
Andrey Ugolkov presents his work the use of 9-ING-41 in treatment-sensitive and treatment-resistant glioblastoma at the Society of Neuro Oncology meeting. (see attachment)
October 29, 2015
Actuate Forms Scientific Advisory Board
April 20, 2015
Drs. Dubrovsky and Ugolkov present research on GSK-3B and its role in neuroblastoma and glioblastoma at the AACR meeting in April 20. (Poster 1) (Poster 2)
April 16, 2015
License agreements are executed with both UIC and Northwestern for the technology and know-how that serves as the foundational intellectual property for Actuate Therapeutics.
Jan 16, 2015
Company is incorporated as Apotheca Therapeutics, Inc, a Delaware C Corp, with Headquarters in Fort Worth, Texas.
